Pepticom Raises $6.6M in Series A1 Funding to Advance AI-Driven Peptide Therapeutics
Pepticom is transforming drug discovery with its AI-driven platform, creating precision therapies for high-need therapeutic areas such as autoimmune disorders.
Company Name: Pepticom
Location: Jerusalem, Israel
Industry: AI-Driven Peptide-Based Therapeutics
Funding Details:
Amount: $6.6M (Series A1)
Investor: Japan Israel High Tech Ventures 2 LP (Lead), with participation from existing investors
Purpose of Investment:
The funds will support the acceleration of Pepticom’s oral IL-17 inhibitor program, targeting advanced treatments for autoimmune diseases.
Leadership:
CEO: Immanuel Lerner
Product:
Pepticom leverages AI to design peptide-based therapeutics that address complex biological challenges. Key highlights include:
- Oral IL-17 Inhibitor Program: Developing two families of fully synthetic, small cyclic peptidomimetic inhibitors with nanomolar activity targeting IL-17A and IL-17F isoforms.
- Innovative Design: Utilizing non-natural amino acids to create compounds with increased stability and extended half-life in both in vitro and in vivo settings.
- Rapid Milestones: Achieving significant advancements in record time and at lower costs.
About the Company:
Pepticom is transforming drug discovery with its AI-driven platform, creating precision therapies for high-need therapeutic areas such as autoimmune disorders. By harnessing the unique properties of peptides, the company is pioneering new solutions for some of medicine’s most complex challenges.
With its latest funding, Pepticom is positioned to revolutionize peptide-based drug development and deliver groundbreaking treatments for serious diseases.
